Navigation Links
Cambrex Announces Significant New Supply Agreement
Date:8/14/2012

EAST RUTHERFORD, N.J., Aug. 14, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") announced that it has entered into an agreement to supply an active pharmaceutical ingredient for a customer's Phase 3 program during 2013 and 2014.  Under this non-exclusive supply arrangement, Cambrex will manufacture and deliver Phase 3 and pre-launch quantities of this product candidate. 

This agreement is expected to contribute over $20 million to 2013 revenues and potentially more in 2014 depending on regulatory developments, the timing of completion of Cambrex's capacity expansion related to this opportunity and meeting key product delivery milestones.  The agreement does not impact sales or profits in 2012 and does not include any commitments beyond 2014.  While there are certain protections built into the agreement related to early termination, the extent of this project's contribution to Cambrex is contingent upon our customer's Phase 3 program not being terminated or meaningfully reduced for any reason.

Shawn Cavanagh, Chief Operating Officer, said, "We are privileged to partner with this important new customer on such a significant project and are excited about successfully executing our capacity expansion so we can help our customer get this product candidate to market as quickly as possible.  Our customers routinely cite our excellent quality systems, regulatory record and experienced personnel as reasons for awarding us business, and each of these factors played a role in Cambrex being chosen for this project.  We continue to be excited about the pipeline of opportunities in front of us and are focused on making sure we have the resources in place to facilitate ongoing growth."

In order to meet the demand under the new agreement, Cambrex will invest significant capital over the remainder of 2012 and in early 2013 to expand our multipurpose large scale cGMP assets.  Consequently, the Company is re
'/>"/>

SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
2. Cambrex Reports First Quarter 2012 Results
3. Sunpeaks Ventures Announces Second Quarter 2012 Results
4. MultiCell Announces Results of Shareholders Meeting
5. ChemAxon Announces New Version of chemicalize.org for Tablet PCs
6. Naturs Design Announces the Dreams With Hope Tour, a Nationwide Sleep Awareness Campaign
7. ADVENTRX Announces Appointment Of Chief Medical Officer
8. FDAnews Announces Medical Device Mobile Apps Virtual Conference
9. Dehaier Medical Announces 2012 Second Quarter and Six Month Financial Results
10. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
11. WuXi PharmaTech Announces Second-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... 2011 iAdvantage Software, Inc. , ... life science studies, today announced that BioTox Sciences ... San Diego, California, is deploying the eStudy™ ... preclinical/nonclinical studies . (Logo: http://photos.prnewswire.com/prnh/20110309/CL62195LOGO) ...
... Reportlinker.com announces that a new market research ... Cancer Vaccines - Pipeline Assessment and Market ... Cancer Vaccines - Pipeline Assessment ... SummaryGlobalData, the industry analysis specialist,s new report, "Cancer ...
Cached Medicine Technology:BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies 2BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies 3Reportlinker Adds Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:7/11/2014)... July 11, 2014 Global enterprises today ... to outsource day-to-day management activities. Managed services offer these ... expenses. The economic slowdown resulted into rising operational costs ... expenses is considered to be the global market driver ... , The global managed services market is estimated to ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... who drink more than 15 drinks of alcohol a ... like anxiety disorder and depression. ,Researchers of University ... the study said that there is a significant link ... research study has been the largest longitudinal study in ...
... Health, US, have found out //that almost 50% of the ... early as the teenage and may remain undetected for a ... in spite of efficient treatments available, patients stay untreated for ... disorders once diagnosed, difficult to treat as they become more ...
... Gold nanoparticles may be used to detect cancer, says a ... ,The father and son research team had been able ... cells, a process that will make the tracing of cancer ... called epidermal growth factor receptor (EFGR) over their surface. This ...
... screening of the mouth by trained health workers can help ... the oral cancer mortality rate. ,A research done by ... possible to visually screen people for oral cancer in order ... of oral cancer patients. ,Oral cancer is the growth ...
... women take is affected by factors like stress, mood, //anxiety ... the American Dietetic Association. ,Diet in pregnancy is very ... contain the food elements like folic acid and other vitamins ... women who are more often exhausted or stressed tend to ...
... cancer may have higher risks of having cognitive// impairment ... of Southern California had found that patients who survived ... as much risk as their healthy counterparts of having ... of cancer and their twins with the help of ...
Cached Medicine News:
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
... for applications such as vasectomy that ... ,The autoclavable handpiece with six-foot cord ... cautery electrodes, allowing the physician to ... wide variety of procedures., ,The 2201 ...
No Scalpel Vasectomy Hemostat 5 1/2" (14cm), smooth sharp point, curved, gold finger rings...
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company....
Medicine Products: